To date, JSP191 has been evaluated in more than 120 healthy volunteers and patients. This humanized antibody is currently being studied in Jasper-sponsored clinical trials in hematopoietic stem cell transplantation.
- SCID: Phase 1/2 dose-escalation and expansion trial is evaluating JSP191 as a sole conditioning agent to achieve donor stem cell engraftment in patients undergoing hematopoietic stem cell transplantation for SCID, which is potentially curable only by this type of treatment. (NCT02963064)
- AML/MDS: A Phase 1 trial is evaluating JSP191 in combination with another low-intensity conditioning regimen in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing hematopoietic stem cell transplantation. (NCT04429191)
Initial results from JSP191 clinical studies have been presented at the American Society of Hematology (ASH) 2021 annual meeting for SCID and at the Transplant and Cellular Therapy (TCT) 2022 conference for AML/MDS.
Additional studies will advance JSP191 as a conditioning agent for patients with other genetic disorders (Fanconi’s Anemia, Sickle Cell Disease, X-linked SCID) and autoimmune diseases (lupus, multiple sclerosis, scleroderma).